AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01364870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TENS
Description: High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
Study NCT03554421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Description: A 20Hz electrical current is given via an electrode inserted through the skin over the posterior tibial nerve above the medial malleolus of the foot and the nerve is stimulated until a motor reflex of the big toe is acheived. Treatment is then continued for 30 minutes at this level. The treatment is then repeated for a total of 10 sessions within a 2 week period.
Study NCT01349556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: tretinoin 0.025% cream
Study NCT03742531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
Study NCT01108900 — intervention group
Intervention type: DRUG
Intervention: sildenafil
Description: tables, 25,50,100 mg, on demand, 1 month
Study NCT05049044 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
Study NCT03504098 — intervention group
Intervention type: BEHAVIORAL
Intervention: nutrition consult
Description: Post-lung cancer operation diet pattern
Study NCT03751839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemical Tests
Description: The investigators will perform blood tests in every participant.
Study NCT02945332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Required supervised walking
Description: The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
Study NCT02945332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-required supervised walking
Description: The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
Study NCT02945332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Flex
Study NCT02945332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Flex
Study NCT03366922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artemisia Annua, Moringa oleifera
Description: As described above
Study NCT03366922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisia Annua, Moringa oleifera
Description: As described above
Study NCT00387894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
Study NCT01556126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amphilimus Eluting Stent (CRE8)
Description: Sirolimus formulated coronary eluting stent
Study NCT04137354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent placebo iron supplement
Description: Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
Study NCT04137354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent placebo iron supplement
Description: Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
Study NCT04137354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent iron supplement
Description: Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
Study NCT04137354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vitamin A
Description: Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
Study NCT04137354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Vitamin A
Description: Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
Study NCT04137354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-dose Vitamin A supplement
Description: Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
Study NCT01171092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib and G-CSF
Description: Bortezomib injection:~1.3mg/m2 11 days before and 8 days before the stem cell collection~G-CSF injection:~10mcg/kg on days -4 to day -1 once daily
Study NCT05795530 — intervention group
Intervention type: PROCEDURE
Intervention: cochlear implantation
Description: surgery for bilateral hearing loss
Study NCT03685838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings
Description: Class II above knee compression stockings
Study NCT04062448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420 mg will be administered orally.
Study NCT04062448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 will be administered intravenously.
Study NCT03168568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/Sacubitril or placebo
Description: tablet (double dummy)
Study NCT01174056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: 600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
Study NCT01174056 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pioglitazone placebo
Description: Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
Study NCT01174056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone placebo
Description: Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
Study NCT01174056 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Zileuton placebo
Description: Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
Study NCT01174056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton placebo
Description: Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
Study NCT01174056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: PPAR-gamma agonist
Study NCT00680875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Click City
Description: School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
Study NCT03751839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Osteodensitometry
Description: The investigators will perform an osteodensitometry in every participant.
Study NCT03751839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Tests
Description: The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.
Study NCT03168568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan or placebo
Description: tablet (double dummy)
Study NCT01271569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fospropofol disodium
Description: Fospropofol disodium： 0.5g
Study NCT04558190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Lipid infusion
Study NCT04558190 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Lipid infusion
Study NCT04558190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Lipid infusion
Study NCT04558190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Oral administration of MitoQ capsules
Study NCT04558190 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol
Description: Beta2-agonist infusion
Study NCT03751839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HR-QCT
Description: The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.
Study NCT03751839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.
Study NCT01923298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Study NCT02216656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT02216656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580 low dose
Description: Oral administration
Study NCT02216656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580 middle dose
Description: Oral administration
Study NCT02216656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580 high dose
Description: Oral administration
Study NCT02216656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN1493
Description: Oral administration
Study NCT02482714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity.
Description: Have subject do moderate physical activity.
Study NCT02482714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity.
Description: Have subject do moderate physical activity.
Study NCT01800773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
Study NCT01800773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
Study NCT03745976 — intervention group
Intervention type: PROCEDURE
Intervention: questionnaire and Xray for all patients
Description: questionnaire and Xray for all patients
Study NCT02497040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: local injection
Study NCT02497040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: local injection
Study NCT02497040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local injection
Study NCT02497040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: local injection
Study NCT02497040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: local injection
Study NCT01303406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
Study NCT01303406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01990131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment
Study NCT01990131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Health Education Training
Study NCT04333407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75mg
Description: • If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.
Study NCT04333407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: • If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated
Study NCT03446014 — intervention group
Intervention type: DEVICE
Intervention: Fitbit Sub-Study
Study NCT04333407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 MG
Description: * If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated~* If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated
Study NCT04333407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: • If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated
Study NCT04333407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: • If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.
Study NCT02125942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Central Meditation and Imagery Therapy
Description: mindfulness, guided imagery, meditation
Study NCT00809471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 30 minutes orally prior to initiation of sexual activity
Study NCT00809471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 30 minutes orally prior to initiation of sexual activity
Study NCT01514058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA first, followed by CRCP with bilinary stenting
Description: EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
Study NCT01514058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with stent placement, followed by EUS-FNA
Description: ERCP with stent placement, followed by EUS-FNA
Study NCT03902184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH4102
Description: Patients will receive a flat dose of 750mg
Study NCT01968525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pre-oxygen
Description: 3 min of preoxygenation before anesthesia induction.
Study NCT03243422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Successful aging health education intervention
Description: The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization.
Study NCT03243422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hearing intervention
Description: The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
Study NCT01963338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal injection in the forearm (0,1cc NaCl 0,9%)
Description: This injection is conducted by the newly developed device.
Study NCT01963338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal injection in the upper arm (0,1cc NaCl 0,9%)
Description: This injection is conducted by the newly developed device in the upper arm (deltoid region).
Study NCT01963338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)
Description: This injection is conducted by needle and syringe in the upper arm (deltoid region).
Study NCT04272619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIVE-R Life Education
Description: A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
Study NCT04538417 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cooled Radiofrequency Ablation
Description: RFA procedures will be performed with modification accounting for appropriate C-RFA technique. Participant will be positioned prone and skin prepped with chloroprep. Ultrasound probe will be placed on residual limb at a transverse angle in order to view the nerve and associated neuroma in long-axis. The probe will be advanced to the site of the stump neuroma. C-RFA electrode will be placed adjacent to neuroma. Needle will be connected via wire to a cooled radiofrequency generator. Motor and sensory testing will be performed to reproduce or exacerbate the RLP and / or PLP. At the site of the neuroma, 2 mL of local anesthetic will be injected through the needle. C-RFA lesions will be created by using the typical C-RFA protocol. Upon completion needle will be removed. Following ablation, 0.5 mL of 0.5% bupivacaine will be injected at the site of the ablated neuroma to provide post procedure analgesia.
Study NCT03967769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow nasal Cannula
Description: Apnoeic Oxygenation by High Flow Nasal Cannulae
Study NCT04748081 — intervention group
Intervention type: PROCEDURE
Intervention: hepatectomy
Description: hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4)
Study NCT02022579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE-MRI and DWI
Description: DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
Study NCT05865054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Combined orbital and cranial vessel wall MRI
Study NCT00536926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home spirometry with data transfer via cell phone
Description: home spirometry recording